Category: Include on Menu
-
Freightos plans workforce reduction of up to 15% under cost-saving initiative
Freightos Limited (NASDAQ:CRGO) said it will reduce its global workforce by up to 15% as part of a cost optimization program aimed at improving operational efficiency and helping the company reach adjusted EBITDA breakeven by the end of 2026. The freight technology platform expects to record roughly $1.3 million in one-time restructuring expenses, mainly tied…
-
Kodiak Sciences shares jump on encouraging Phase 3 trial results
Shares of Kodiak Sciences Inc. (NASDAQ:KOD) surged about 26% on Thursday after the company reported positive topline data from GLOW2, its second Phase 3 clinical trial evaluating Zenkuda (tarcocimab tedromer) for the treatment of diabetic retinopathy. In the study, 62.5% of patients treated with Zenkuda achieved at least a two-step improvement in their diabetic retinopathy…
-
WhiteFiber shares slide 11% after wider-than-expected fourth-quarter loss
WhiteFiber, Inc. (NASDAQ:WYFI) reported a fourth-quarter loss on Thursday that fell well short of analyst expectations, sending the company’s shares down about 11.4% in pre-market trading. The AI infrastructure provider posted an adjusted loss of $0.67 per share for the quarter, significantly deeper than the consensus forecast of a $0.06 loss. Revenue for the period…
-
Novocure shares gain on encouraging pancreatic cancer trial results
Shares of Novocure (NASDAQ:NVCR) rose about 5% on Thursday after the company reported positive topline data from its Phase 2 PANOVA-4 clinical trial evaluating Tumor Treating Fields (TTFields) therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study achieved its primary endpoint, demonstrating a statistically significant improvement in disease control rate compared with a historical…
-
Lovesac shares jump 18% after fourth-quarter earnings and revenue top forecasts
Shares of The Lovesac Company (NASDAQ:LOVE) surged about 18% in pre-market trading on Thursday after the furniture retailer reported fourth-quarter results that exceeded Wall Street expectations. Investors reacted positively to the company’s performance despite ongoing macroeconomic pressures affecting the retail sector. For the quarter ended February 1, 2026, Lovesac posted adjusted earnings per share of…
-
Snap shares slip after EU opens investigation into child safety on Snapchat
Shares of Snap (NYSE:SNAP) fell about 1.6% in premarket trading on Thursday after the European Union launched an investigation into whether Snapchat is adequately addressing risks related to child grooming and the sale of illegal products on its platform. The inquiry is being carried out under the EU’s Digital Services Act, which requires major online…
-
Soligenix secures EU orphan drug designation for Behçet’s disease therapy
Soligenix Inc. (NASDAQ:SNGX) said the European Commission has granted orphan drug designation to dusquetide, the active compound in its investigational therapy SGX945, for the treatment of Behçet’s Disease. The designation follows a favorable opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products, which evaluated previously published Phase 2a clinical trial data for the…
-
REX American Resources tops Q4 profit forecasts as tax credits boost results
REX American Resources Corporation (NYSE:REX) reported fourth-quarter earnings on Thursday that surpassed analyst expectations, largely supported by newly available tax credits, although revenue came in slightly below forecasts. The ethanol producer’s shares slipped about 0.22% in pre-market trading after the announcement, suggesting a restrained reaction from investors to the mixed results. For the fourth quarter,…
-
Wave Life Sciences shares plunge 30% despite encouraging obesity trial results
Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) dropped about 30% on Thursday even after the company released interim Phase 1 data from its INLIGHT study evaluating WVE-007 as a potential treatment for obesity. According to the company, six-month results showed that a single 240 mg dose of WVE-007 produced a placebo-adjusted 14% reduction in visceral…
-
Sensient commits up to $250 million to boost natural color production capacity
Sensient Technologies Corporation (NYSE:SXT) said it plans to invest as much as $250 million to expand its manufacturing capacity, supply chain infrastructure and workforce dedicated to natural food colors, responding to rising demand in the United States for alternatives to synthetic coloring. The company marked the start of a major expansion project at its natural…